Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Operating Leases: 2020-2022

Historic Operating Leases for Arcus Biosciences (RCUS) over the last 2 years, with Sep 2022 value amounting to $119.2 million.

  • Arcus Biosciences' Operating Leases rose 130.55% to $119.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $119.2 million, marking a year-over-year increase of 130.55%. This contributed to the annual value of $116.9 million for FY2021, which is 666.82% up from last year.
  • Arcus Biosciences' Operating Leases amounted to $119.2 million in Q3 2022, which was down 1.77% from $121.3 million recorded in Q2 2022.
  • Arcus Biosciences' 5-year Operating Leases high stood at $121.3 million for Q2 2022, and its period low was $14.7 million during Q1 2021.
  • Its 3-year average for Operating Leases is $75.8 million, with a median of $83.5 million in 2021.
  • Data for Arcus Biosciences' Operating Leases shows a peak YoY soared of 680.74% (in 2022) over the last 5 years.
  • Quarterly analysis of 3 years shows Arcus Biosciences' Operating Leases stood at $15.2 million in 2020, then surged by 666.82% to $116.9 million in 2021, then surged by 130.55% to $119.2 million in 2022.
  • Its last three reported values are $119.2 million in Q3 2022, $121.3 million for Q2 2022, and $114.8 million during Q1 2022.